FDA Seeks More Data on Forest and Gedeon Richter’s Schizophrenia Drug

$25.00
The FDA has handed Forest Laboratories and Gedeon Richter a complete response letter asking for more data on cariprazine, the companies’ drug candidate to treat schizophrenia and manic or mixed episodes of bipolar I disorder in adults.